<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860896</url>
  </required_header>
  <id_info>
    <org_study_id>GB004-1101</org_study_id>
    <nct_id>NCT03860896</nct_id>
  </id_info>
  <brief_title>GB004 in Adult Subjects With Active Ulcerative Colitis</brief_title>
  <official_title>A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GB004 in Adult Subjects With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gossamer Bio Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, randomized, double-blind-, placebo-controlled, multi-center study to
      evaluate the safety, tolerability, and PK of GB004 in adult subjects with active ulcerative
      colitis. Target engagement and effect of GB004 on pharmacodynamic biomarkers will be
      assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The safety, tolerability, pharmacokinetics, and pharmacodynamics of GB004 will be explored in
      a Phase 1b randomized controlled trial in adults subjects with active ulcerative colitis
      (UC). Subjects will be evaluated based on incidence of AEs, laboratory parameters, GB004
      serum and colonic tissue concentrations, and changes in the signs and symptoms of UC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2019</start_date>
  <completion_date type="Actual">December 17, 2019</completion_date>
  <primary_completion_date type="Actual">December 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>56 Days</time_frame>
    <description>To evaluate the safety and tolerability of GB004 for 56 days in terms of incidence of treatment emergent adverse events reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to Reach Maximum Concentration (Tmax) of GB004</measure>
    <time_frame>Day 1 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of GB004</measure>
    <time_frame>Day 1 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) of GB004</measure>
    <time_frame>Day 1 to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>GB004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB004 for oral administration daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for oral administration daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB004</intervention_name>
    <description>GB0004 high dose</description>
    <arm_group_label>GB004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB004</intervention_name>
    <description>GB004 low dose</description>
    <arm_group_label>GB004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-74, receiving therapy for active ulcerative colitis confirmed by Mayo
             Score assessment, and evidence of colonic inflammation.

        Exclusion Criteria:

          -  Evidence of Crohn's disease, indeterminate colitis, or presence of bacterial or
             parasitic infection.

          -  Patients receiving biologic agents and experimental agents are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Delta Research Partners</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arensia Exploratory Medicine</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMSI Republican Clinical Hospital &quot;Timofei Mosneaga&quot;</name>
      <address>
        <city>Chisinau</city>
        <zip>MD2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

